Skip to content
Lirentelimab
Lirentelimab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DuodenitisD004382K29.8145
GastritisD005756EFO_0000217K29.7235
GastroenteritisD005759EFO_1001463K52.9213
Eosinophilic esophagitisD057765EFO_0004232K20.0111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic urticariaD000080223L50.822
Atopic dermatitisD003876EFO_0000274L2011
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients22
Systemic mastocytosisD034721C96.2111
KeratoconjunctivitisD007637H16.211
Allergic conjunctivitisD003233EFO_0007141H10.4411
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLIRENTELIMAB
INNlirentelimab
Description
Lirentelimab (sold under the brand name AK002) is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). In a randomized clinical trial, lirentelimab was found to improve eosinophil counts and symptoms in individuals with eosinophilic gastritis and duodenitis. Adverse reactions include infusion reactions, which are mild to moderate and typically occur following the first infusion.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)LIRENTELIMAB
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB7QUH
CAS-ID
RxCUI
ChEMBL IDCHEMBL4297878
ChEBI ID
PubChem CID
DrugBank
UNII IDSWS48LJU3T (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 75 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details